Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from risperidone to aripiprazole in outpatient schizophrenia
2005-000472-40Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aripiprazole in schizophrenia (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of patients who discontinue due to adverse events. Started Jun 2005; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2005-000472-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000472-40.